Study of Euphoria Caused by Remimazolam Sedation During Gastroscopy or Colonoscopy and Related Factors

What this Trial Is About

Researchers are investigating how often remimazolam, a short-acting sedative, causes feelings of euphoria in patients undergoing gastrointestinal endoscopy, including gastroscopy and colonoscopy. This study explores factors related to this euphoria and aims to improve sedation practices to help patients feel more comfortable and satisfied during these procedures. The study is observational and focuses on sedation effects and patient experience. Participants receive sedation according to standard guidelines, starting with sufentanil and lidocaine gel for oral preparation, followed by remimazolam administered intravenously. The initial dose of remimazolam is 0.2-0.3 mgkg, with additional 2.5 mg doses given as needed to maintain sedation. The sedative is chosen for its quick onset and recovery, with minimal effects on breathing and heart function. Data will be collected on patient demographics, euphoria scores before sedation and two hours after the procedure, safety indicators, and satisfaction. During the study, patients will be monitored from before sedation until two hours after full recovery. Researchers will assess euphoria using a specific scale and record safety information and patient satisfaction levels. The study lasts throughout the procedure and recovery period, aiming to understand how remimazolam affects patient comfort and cooperation, with the goal of optimizing sedation protocols.

Study on the Feelings of Euphoria Caused by Remimazolam During Gastroscopy and Colonoscopy and Their Related Factors